|
1
|
Hoffman RM and Sanchez R: Lung cancer
screening. Med Clin North Am. 101:769–785. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zappa C and Mousa SA: Non-small cell lung
cancer: Current treatment and future advances. Transl Lung Cancer
Res. 5:288–300. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Blandin Knight S, Crosbie PA, Balata H,
Chudziak J, Hussell T and Dive C: Progress and prospects of early
detection in lung cancer. Open Biol. 7(pii): 1700702017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Clement JH, Sänger J and Höffken K:
Expression of bone morphogenetic protein 6 in normal mammary tissue
and breast cancer cell lines and its regulation by epidermal growth
factor. Int J Cancer. 80:250–256. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ro TB, Holt RU, Brenne AT, Hjorth-Hansen
H, Waage A, Hjertner O, Sundan A and Borset M: Bone morphogenetic
protein-5, −6 and −7 inhibit growth and induce apoptosis in human
myeloma cells. Oncogene. 23:3024–3032. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chheang S and Brown K: Lung cancer
staging: Clinical and radiologic perspectives. Semin Intervent
Radiol. 30:99–113. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen Q, Wang L, Ma Y, Wu X, Jin L and Yu
F: Increased hepcidin expression in non-small cell lung cancer
tissue and serum is associated with clinical stage. Thorac Cancer.
5:14–24. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Domvri K, Zarogoulidis P, Darwiche K,
Browning RF, Li Q, Turner JF, Kioumis I, Spyratos D, Porpodis K,
Papaiwannou A, et al: Molecular targeted drugs and biomarkers in
NSCLC, the evolving role of individualized therapy. J Cancer.
4:736–754. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kraunz KS, Nelson HH, Liu M, Wiencke JK
and Kelsey KT: Interaction between the bone morphogenetic proteins
and Ras/MAP-kinase signalling pathways in lung cancer. British J
Cancer. 93:949–952. 2005. View Article : Google Scholar
|
|
10
|
Vukicevic S and Grgurevic L: BMP-6 and
mesenchymal stem cell differentiation. Cytokine Growth Factor Rev.
20:441–448. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Otani H, Otsuka F, Inagaki K, Suzuki J and
Makino H: Roles of bone morphogenetic protein-6 in aldosterone
regulation by adrenocortical cells. Acta Med Okayama. 64:213–218.
2010.PubMed/NCBI
|
|
12
|
Tandon M, Gokul K, Ali SA, Chen Z, Lian J,
Stein GS and Pratap J: Runx2 mediates epigenetic silencing of the
bone morphogenetic protein-3B (BMP-3B/GDF10) in lung cancer cells.
Mol Cancer. 11:272012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Seckinger A, Meissner T, Moreaux J,
Goldschmidt H, Fuhler GM, Benner A, Hundemer M, Rème T, Shaughnessy
JD Jr, Barlogie B, et al: Bone morphogenic protein 6: A member of a
novel class of prognostic factors expressed by normal and malignant
plasma cells inhibiting proliferation and angiogenesis. Oncogene.
28:3866–3879. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wach S, Schirmacher P, Protschka M and
Blessing M: Overexpression of bone morphogenetic protein-6 (BMP-6)
in murine epidermis suppresses skin tumor formation by induction of
apoptosis and downregulation of fos/jun family members. Oncogene.
20:7761–7769. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Takahashi M, Otsuka F, Miyoshi T, Otani H,
Goto J, Yamashita M, Ogura T, Makino H and Doihara H: Bone
morphogenetic protein 6 (BMP-6) and BMP7 inhibit estrogen-induced
proliferation of breast cancer cells by suppressing p38
mitogen-activated protein kinase activation. J Endocrinol.
199:445–455. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim IY, Lee DH, Lee DK, Kim BC, Kim HT,
Leach FS, Linehan WM, Morton RA and Kim SJ: Decreased expression of
bone morphogenetic protein (BMP) receptor type II correlates with
insensitivity to BMP-6 in human renal cell carcinoma cells. Clin
Cancer Res. 9:6046–6051. 2003.PubMed/NCBI
|
|
17
|
Johnsen IK, Kappler R, Auernhammer CJ and
Beuschlein F: Bone morphogenetic proteins 2 and 5 are
down-regulated in adrenocortical carcinoma and modulate adrenal
cell proliferation and steroidogenesis. Cancer Res. 69:5784–5792.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kraunz KS, Nelson HH, Liu M, Wiencke JK
and Kelsey KT: Interaction between the bone morphogenetic proteins
and Ras/MAP-kinase signaling pathways in lung cancer. Br J Cancer.
93:949–952. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Radpour R, Kohler C, Haghighi MM, Fan AX,
Holzgreve W and Zhong XY: Methylation profiles of 22 candidate
genes in breast cancer using high-throughput MALDI-TOF mass array.
Oncogene. 28:2969–2978. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Daibata M, Nemoto Y, Bandobashi K, Kotani
N, Kuroda M, Tsuchiya M, Okuda H, Takakuwa T, Imai S, Shuin T and
Taguchi H: Promoter hypermethylation of the bone morphogenetic
protein-6 gene in malignant lymphoma. Clin Cancer Res.
13:3528–3535. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kimura K, Toyooka S, Tsukuda K, Yamamoto
H, Suehisa H, Soh J, Otani H, Kubo T, Aoe K, Fujimoto N, et al: The
aberrant promoter methylation of BMP3b and BMP-6 in malignant
pleural mesotheliomas. Oncol Rep. 20:1265–1268. 2008.PubMed/NCBI
|
|
22
|
Taniguchi A, Nemoto Y, Yokoyama A, Kotani
N, Imai S, Shuin T and Daibata M: Promoter methylation of the bone
morphogenetic protein-6 gene in association with adult T-cell
leukemia. Int J Cancer. 123:1824–1831. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang S, Zhong C, Frenkel B, Reddi AH and
Roy-Burman P: Diverse biological effect and Smad signaling of bone
morphogenetic protein 7 in prostate tumor cells. Cancer Res.
65:5769–5777. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Esteller M: Epigenetic gene silencing in
cancer: The DNA hypermethylome. Hum Mol Genet 16 Spec No.
1:R50–R59. 2007. View Article : Google Scholar
|
|
25
|
Li S, Sheng B, Zhao M, Shen Q, Zhu H and
Zhu X: The prognostic values of signal transducers activators of
transcription family in ovarian cancer. Biosci Rep. 37(pii):
BSR201706502017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ma YM and Zhao S: Prognostic values of
aldehyde dehydrogenase 1 isoenzymes in ovarian cancer. Onco Targets
Ther. 9:1981–1988. 2016. View Article : Google Scholar : PubMed/NCBI
|
